The FDA’s Center for Devices and Radiological Health (CDRH) is announcing a partnership with the Bill and Melinda Gates Foundation to create new analytical methods to help the development of breath-based diagnostic devices for disease detection in underserved populations

More than half of patients (60%) diagnosed with advanced forms of lung cancer who took lorlatinib were still alive five years later with no progression in their disease, data presented at the world’s largest cancer conference showed. The rate was 8% in patients treated with a standard drug, the trial found.

American Lung Association’s report examines toll of lung cancer state-by-state, underscores urgent need for more people to be screened

A quartet of companies on Wednesday were selected among the 44 companies that presented at MedCity INVEST, MedCity News' healthcare investing conference.

Recent advancements in material science, synthetic biology, and engineering have paved the way for wearable breath analysis technologies, promising a new era of non-invasive diagnostics.

In an exciting development in the fight against lung cancer, the University of Louisville has teamed up with Breath Diagnostics to pioneer a groundbreaking detection technology.